Holdings of Octagon Capital Advisors LP
26 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 73.2 % of the equity sleeve
Sector breakdown
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|
| 1 | US | 24 | 737M $ | 89.40 % |
| 2 | FR | 2 | 87.4M $ | 10.60 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|
| 1 | Dianthus Therapeutics Inc | 1,946,667 | 163.4M $ | |
| 2 | Cogent Biosciences Inc | 2,350,000 | 90.5M $ | |
| 3 | Abivax SA | 677,000 | 75.4M $ | |
| 4 | Alumis Inc | 2,830,700 | 62.4M $ | |
| 5 | ArriVent Biopharma Inc | 1,971,054 | 45.5M $ | |
| 6 | Taysha Gene Therapies Inc | 8,859,911 | 39.6M $ | |
| 7 | Kymera Therapeutics Inc | 425,000 | 35.4M $ | |
| 8 | Mirum Pharmaceuticals Inc | 338,900 | 31.3M $ | |
| 9 | BioAge Labs Inc | 1,748,000 | 30.6M $ | |
| 10 | CENTESSA PHARMACEUTICALS PLC | 750,000 | 29.8M $ | |
| 11 | KalVista Pharmaceuticals Inc | 1,450,000 | 29.2M $ | |
| 12 | Terns Pharmaceuticals Inc | 530,000 | 27.9M $ | |
| 13 | Ocular Therapeutix Inc | 3,166,600 | 26.8M $ | |
| 14 | Palisade Bio Inc | 10,276,317 | 18M $ | |
| 15 | Trevi Therapeutics Inc | 1,485,000 | 17.7M $ | |
| 16 | Disc Medicine Inc | 270,000 | 17.3M $ | |
| 17 | Aktis Oncology Inc | 960,847 | 17.2M $ | |
| 18 | Context Therapeutics Inc | 5,250,000 | 13.8M $ | |
| 19 | Precision BioSciences Inc | 2,236,732 | 12.3M $ | |
| 20 | DBV Technologies SA | 574,200 | 12M $ | |
| 21 | Unicycive Therapeutics Inc | 1,000,000 | 6.6M $ | |
| 22 | BridgeBio Oncology Therapeutics Inc | 719,000 | 6.4M $ | |
| 23 | Lexeo Therapeutics Inc | 1,100,000 | 6.3M $ | |
| 24 | Perspective Therapeutics Inc | 791,555 | 3.3M $ | |
| 25 | Evommune Inc | 143,472 | 3.3M $ | |
| 26 | Gossamer Bio Inc | 7,750,000 | 2.5M $ | |